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DBP at 12 months in group A, the maintenance of normal hctEffects of normal hematocrit on ambulatory blood pressure in
levels did not affect the abnormal diurnal BP pattern seen atepoetin-treated hemodialysis patients with cardiac disease.
moderately anemic hct levels in most patients.Background. Hypertension is a recognized complication of
partial correction of anemia with recombinant human erythro-
poietin (epoetin) in hemodialysis patients. We used interdia-
lytic ambulatory blood pressure (ABP) monitoring to study the Hypertension has been associated with the treatmenteffects of partially corrected anemia versus normal hematocrit
of anemia with recombinant human erythropoietin(hct) on BP in hemodialysis patients.
(epoetin) in chronic hemodialysis patients [1, 2]. Ambu-Methods. Repeated interdialytic ABP monitoring was per-
formed for up to one year in 28 chronic hemodialysis patients latory blood pressure (ABP) monitoring has been used
with cardiac disease who were randomized to achieve and to study the effect on BP of partial correction of anemia
maintain normal hct levels (42 6 3%, group A) or anemic hct in hemodialysis patients [3–8]. In these studies, in whichlevels (30 6 3%, group B) with epoetin. Routine BP measure-
anemia was only partially corrected to hematocrit (hct)ments obtained at dialysis treatments were also evaluated.
levels at or below the currently recommended target hctResults. Mean hct levels were 30.7 6 0.7% in group A and
30.6 6 0.7% in group B at baseline, then 39.3 6 1.2% (group A) range of 33 to 36% [9], the mean 24-hour systolic and
and 33.5 6 0.6% (group B) at four months, and 42.0 6 1.1% diastolic ABP components increased, with increases in
(group A) and 30.4 6 1.0% (group B) at 12 months. Baseline both daytime and nighttime BPs. None of the studiesABP and routine dialysis unit BP levels were not different
used repeated interdialytic ABP monitoring over an ex-between the groups. At 2, 4, 8, and 12 months of follow-up,
tended time period, and none included patients undergo-there were no statistically significant differences in any BP
parameters between groups or increases in any BP parameters ing the correction of anemia to normal hct levels.
in either group A or group B patients compared with baseline. In 1992, a large multicenter randomized open-label
At 12 months, the mean nighttime diastolic BP (DBP) in group clinical trial (N 5 1233 patients) was initiated to examine
A patients was slightly but significantly lower than the mean
the risks and benefits of a normal hct (target hct 42%)daytime DBP (daytime DBP 76.6 6 1.9 mm Hg vs. nighttime
and anemic hct (target hct 30%) in hemodialysis patientsDBP 72.9 6 2.1 mm Hg, P , 0.05). The mean daytime and
with cardiac disease. The study was designed to providenighttime BPs were not different from each other at two, four,
and eight months in group A or at any time in group B, and up to five and one-half years of follow-up to assess all-
in both groups, most patients had little diurnal change in BP. cause mortality, nonfatal myocardial infarction, hospital-
Conclusion. Correction of hct to normal with epoetin in ization for cardiac disease, and other cardiac morbiditychronic hemodialysis patients with cardiac disease did not cause
[10]. Because of the concern that correction of hct toincreased BP as assessed by interdialytic ABP monitoring or
normal levels with epoetin in hemodialysis patients couldby the measurement of routine predialysis and postdialysis BP.
There was little diurnal change in systolic or diastolic BP at cause or exacerbate hypertension, particularly while hct
baseline or after correction of anemia to normal levels, and was increasing from 30 to 42%, we performed repeated
although mean nighttime DBP was lower than mean daytime interdialytic ABP monitoring during the first year that
patients were enrolled in this trial at four of the partici-
pating dialysis clinics. This provided an opportunity toKey words: rHuEPO, cardiovascular disease, anemia, interdialytic am-
bulatory blood pressure, hypertension. assess the effects of increasing hct from 30 to 42% with
epoetin and to compare BP over the course of up to oneReceived for publication December 8, 1998
year in patients randomized to these two hct target levels.and in revised form February 9, 1999
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but not others [6, 11–22]. Our study provided the oppor- the first hemodialysis treatment of the week after stan-
dard calibration and was removed just prior to the subse-tunity to compare diurnal BP patterns at moderately
anemic and normal hct levels in chronic hemodialysis quent (midweek) treatment. BPs were recorded every
30 minutes from 0600 to 2100 hours and every 60 minutespatients.
from 2100 to 0600 hours. The postdialysis weight and
the predialysis and postdialysis sitting BP obtained after
METHODS
patients had rested quietly for five minutes were re-
Patient selection and study protocol corded at the first hemodialysis treatment of the week.
ABP recordings that were less than 75% complete wereFifty-seven adult chronic hemodialysis patients from
four dialysis facilities were enrolled in this ancillary repeated the following week, with the most complete
recording used for analysis. In the event of hospitaliza-study, which was part of a larger prospective, random-
ized, multicenter, open-label clinical trial sponsored by tion, ABP monitoring was performed as soon as possible
after hospitalization. Other aspects of dialysis care andAmgen, Inc. (Thousand Oaks, CA, USA). Patients ran-
domized to group A received epoetin as needed to raise BP management were at the discretion of the attending
nephrologist caring for each patient.the hct from a baseline level of approximately 30% to
achieve and maintain a target hct of 42 6 3%. Patients Patients were excluded from analysis if adequate ABP
records were not available for at least the baseline re-randomized to group B received epoetin as needed to
maintain a target hct of 30 6 3%. The hematocrit values cordings and recordings at months 2 and 4 (aside from
one group B patient for whom the baseline recording(%) reported here were calculated by multiplying mea-
sured hemoglobin concentrations (g/dl) by three. The could not be retrieved; however, subsequent data for
months 2, 4, 8, and 12 are included for analysis).anticipated duration for the large multicenter trial was
three years after enrollment of the last patient. For the
Statistical analysisstudy reported here, the planned duration of follow-up
was for up to one year from enrollment. Ambulatory BP recordings were analyzed for daytime
Patients selected for the study had to have been on (0600 to 1800) and nighttime (1800 to 0600) intervals
chronic hemodialysis and receiving epoetin for at least and combined daytime and nighttime (24-hour) BP. The
three months with a stable hct of 30 6 3% for at least mean 24-hour, daytime, and nighttime systolic BP (SBP)
four weeks prior to enrollment and have congestive heart and diastolic BP (DBP) as well as routine dialysis unit BPs
failure (CHF) (defined as the need for hospitalization were compared. Comparisons between the two groups at
or nonroutine ultrafiltration for CHF in the preceding each study period were done using a two-sided t-test and
two years) and/or ischemic heart disease (angina, docu- analysis of variance. Comparisons of on-study measure-
mented coronary artery disease, myocardial infarction). ments to baseline within each group were done using a
Patients with uncontrolled hypertension, a life expec- paired t-test. Values of P , 0.05 were considered to be
tancy of less than six months, NYHA class IV disability, statistically significant. Data are presented as mean 6 sem.
pericardial disease, valvular heart disease likely to re-
quire surgery, myocardial infarction, coronary artery by-
RESULTSpass graft, or percutaneous transluminal coronary angi-
Data are reported here for 28 patients for whom ade-oplasty within three months prior to entry and androgen
quate ABP monitoring records were available from thetherapy were excluded. Informed consent was obtained
following locations: Graduate Hospital, Lombard Dial-from all patients for participation in both trials, after
ysis Facility (Philadelphia, PA; N 5 22 enrolled, 19 com-approval of the study protocols and consent forms by
pleted); University of Mississippi Medical Center, Kid-the Institutional Review Board at each center.
ney Care, Inc. (Jackson, MS; N 5 18 enrolled, 7
Blood pressure monitoring completed); and St. Luke’s Hospital (Kansas City, MO;
N 5 14 enrolled, 2 completed). An additional centerAmbulatory BP monitoring was performed with the
enrolled three patients, none of whom completed suffi-SpaceLabs Ambulatory Blood Pressure monitor 90207
cient ABP recordings to be included in this analysis.(SpaceLabs Medical, Inc., Redmond, WA, USA). The
All patient drop-outs after enrollment with failure toaccuracy and reproducibility of ABP measurements with
complete at least the baseline through month 4 re-this device have been previously established [23]. The
cordings were due to refusal to continue study participa-study protocol initially required ABP monitoring to be
tion and/or inability to obtain adequate ABP recordings.performed at baseline and then monthly for 4 months
Patient drop-outs between months 4 and 12 were alsoand at 8 and 12 months, but was later amended to require
due to refusal to continue study participation and/or theABP monitoring at baseline and months 2, 4, 8, and 12
inability to obtain adequate ABP recordings, except foronly in order to improve patient compliance. The ABP
monitor was placed on the nonaccess arm at the end of one patient with bilateral arm vascular access, one pa-
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Table 1. Patient demographics and baseline blood pressure (BP) levels
Group A (N 5 14) Group B (N 5 14)
Age years 63.8612.7 58.6 68.9
Gender male/female 4/10 5/9
Race Caucasian/African American 3/11 1/13
Diabetes mellitus 7 8
Hypertension
Pre-SBP . 140 mm Hg 8 10
Pre-DBP . 90 mm Hg 1 4
Mean 24-hour SBP . 140 mm Hg 9 9
Mean 24-hour DBP . 90 mm Hg 0 3
Abbreviations are: SBP, systolic blood pressure; DBP, diastolic blood pressure.
Table 2. Mean hematocrit, epoetin doses, ambulatory and dialysis unit blood pressure parameters and weights in Group A
Baseline 2 months 4 months 8 months 12 months
(N 5 14) (N 5 14) (N 5 14) (N 5 9) (N 5 7)
Hematocrit % 30.760.7 35.5 60.9 39.3 61.2 39.1 61.6 42.0 61.1
Epoetin dose U 3 1000 13.262.4 30.2 62.9 38.8 64.2 42.1 66.1 32.2 64.8
24-hour SBP mm Hg 153.067.4 157.9 65.2 152.9 65.6 161.9 67.7 158.7 67.8
24-hour DBP mm Hg 76.862.0 76.2 62.7 75.6 61.9 81.0 63.9 74.7 61.8
D SBP mm Hg 156.767.5 158.1 64.8 152.9 65.3 161.1 67.9 160.6 68.9
D DBP mm Hg 77.461.9 77.0 62.6 76.4 62.0 80.8 63.8 76.6 61.9
N SBP mm Hg 156.867.9 157.6 68.2 153.1 68.1 163.3 67.8 157.0 67.0
N DBP mm Hg 76.062.3 75.5 63.1 74.6 62.1 81.6 64.3 72.9 62.1
Pre-SBP mm Hg 149.864.7 163.0 68.2 155.3 65.4 161.9 611.1 161.0 63.4
Pre-DBP mm Hg 78.363.0 80.8 64.5 75.0 62.3 80.7 64.9 75.9 62.9
Post-SBP mm Hg 149.466.8 143.0 65.3 139.8 64.4 141.2 67.6 147.1 62.7
Post-DBP mm Hg 71.761.9 75.8 62.2 70.8 62.7 76.0 63.8 77.9 66.6
Postdialysis weight kg 69.663.4 68.8 63.4 69.2 63.5 67.1 64.1 65.9 66.3
Abbreviations are: SBP, systolic blood pressure; DBP, diastolic blood pressure; D, daytime; N, nighttime; pre-, pre-dialysis; post-, post-dialysis.
tient who had a stroke, and two patient deaths. Baseline although there were no statistically significant differ-
ences at either time (paired t-test). As a result, the meandemographic and clinical parameters for groups A and
B are shown in Table 1. ambulatory combined daytime and nighttime 24-hour
SBP, daytime SBP, and nighttime SBP tended to beThe mean hct was 30.7 6 0.7% in group A and 30.6 6
0.7% in group B at baseline. Subsequent hct values (P , somewhat lower at months 2 and 4 in group B compared
with group A, but the differences were not statistically0.05 at months 2, 4, 8, and 12 compared with baseline
in group A) and mean weekly epoetin doses are shown significant. There were no statistically significant differ-
ences in mean routine predialysis or postdialysis BP lev-in Tables 2 and 3. Hypertension was slightly more preva-
lent in group B than group A at baseline (Table 1), els between groups at months 2 and 4 or in either group
A or B compared with baseline. In an analysis (pairedalthough the mean dialysis unit BP and ABP parameters
were not statistically significantly different between the t-test) of only those group A patients who had hct of 42 6
3% at month 4 (N 5 8), there were also no statisticallygroups (Tables 2 and 3). There was little diurnal variation
in BP at baseline. In the baseline ABP recordings, only significant differences in any ABP or routine predialysis
or postdialysis BP parameters compared with baseline.one group B patient had a fall in nocturnal SBP of more
than 10% compared with daytime measurements. None Ambulatory 24-hour, daytime, and nighttime SBP at
8 and 12 months in both groups A and B tended to beof the group A patients had a change in either nocturnal
SBP or DBP compared with daytime BP at baseline. somewhat higher than those observed at four months
(Tables 2 and 3), but in neither group were the differ-There were no statistically significant differences in
any of the mean ABP parameters in either group A or ences statistically significant from baseline or month 4
levels. Although ambulatory 24-hour, daytime, and night-B relative to baseline (paired t-test) or between the two
groups at months 2 or 4 (Tables 2 and 3), the time time SBP tended to be somewhat higher in group A than
group B, there were no statistically significant differencesperiod during which hct was increasing in group A. ABP
parameters were stable in group A at months 2 and 4 in any ABP parameters between groups at 8 or 12
months. Mean predialysis SBP tended to be higher at 8relative to baseline (Table 2) but tended to be somewhat
lower in group B compared with baseline (Table 3), and 12 months in group A and at 12 months in group B
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Table 3. Mean hematocrit, epoetin doses, ambulatory and dialysis unit blood pressure parameters and weights in Group B
Baseline 2 months 4 months 8 months 12 months
(N 5 13) (N 5 14) (N 5 14) (N 5 9) (N 5 8)
Hematocrit % 30.660.7 30.9 61.0 33.5 60.6 31.5 61.0 30.4 61.0
Epoetin dose U 3 1000 10.961.7 12.5 62.4 10.1 62.0 5.7 68.3 6.4 62.3
24-hour SBP mm Hg 154.465.9 150.4 65.2 141.2 68.2 146.3 67.6 150.7 64.3
24-hour DBP mm Hg 83.664.2 80.1 63.2 77.2 62.2 76.3 62.9 77.8 62.6
D SBP mm Hg 154.265.9 149.8 65.0 140.9 68.3 143.4 68.3 148.8 65.5
D DBP mm Hg 84.264.3 80.1 63.1 77.9 62.2 76.2 63.2 79.1 63.3
N SBP mm Hg 154.666.2 151.1 65.5 141.6 66.3 144.9 68.6 152.4 64.9
N DBP mm Hg 83.164.2 78.4 63.1 76.2 62.5 74.8 63.4 76.0 63.2
Pre-SBP mm Hg 159.867.0 155.6 65.3 150.4 66.0 138.6 65.9 163.4 67.8
Pre-DBP mm Hg 84.263.5 87.1 63.8 79.1 63.9 76.6 63.2 89.3 63.9
Post-SBP mm Hg 139.266.1 142.5 65.3 138.1 63.6 139.0 65.1 151.2 66.0
Post-DBP mm Hg 76.163.5 80.5 64.2 75.7 63.4 75.1 64.7 82.9 63.0
Postdialysis weight kg 76.964.7 77.5 64.3 76.5 64.3 74.6 64.7 74.4 64.3
At 8 months N 5 10 and at 12 months N 5 9 for hct, epoetin dose and dialysis unit BP, since one patient had irretrievable ABP recordings at both time periods,
but other data available and used for analysis. Abbreviations are as in Table 2.
compared with baseline levels, but none of the mean 10% compared with daytime SBP at two months. At
dialysis unit BP parameters were statistically significantly both four months and eight months, none of the patients
different in either group A or B at 8 or 12 months com- in group A had a nocturnal fall in SBP or DBP of more
pared with baseline, month 2, or month 4 levels (paired than 10% compared with daytime BP, and only one
t-test) or between groups. In an analysis (paired t-test) patient in group B had a nocturnal fall in DBP of more
of only those group A patients who had an hct of 42 6 than 10%. One patient in each group had a nocturnal
3% at month 8 (N 5 8) and month 12 (N 5 6), there decline in DBP of more than 10% compared with day-
were also no statistically significant differences in any time DBP at 12 months; none of the patients in either
ABP or routine predialysis or postdialysis BP parameters group had a decline of nocturnal SBP of more than 10%
compared with baseline. compared with daytime SBP. The mean nighttime DBP
As seen in Tables 2 and 3, the mean weights in groups was slightly but significantly lower than the mean day-
A and B changed little over the course of the year and time DBP (daytime DBP 76.6 6 1.9 mm Hg vs. nighttime
were not statistically significantly different from baseline DBP 72.9 6 2.1 mm Hg, P , 0.05, paired t-test) at 12
at any time (paired t-test). At four months, two patients months in group A (Table 2).
in group A and one in group B had reductions in weight
of 5% or more from baseline, and one in group A and
DISCUSSIONtwo in group B had increases of 5% or more in weight
Hypertension is a recognized complication of treat-from baseline. At 12 months, two patients in group A
ment of anemia in dialysis patients with epoetin [1, 2,and three in group B had weight reductions of 5% or
24]. This is of particular concern now, as the desiredmore compared with baseline, and one group B patient
target hct range for chronic dialysis patients has in-had an increase in weight of 5% or more compared with
creased over the last few years [9]. Our findings suggestbaseline.
that hct normalization in chronic hemodialysis patientsChanges of antihypertensive medications were infre-
with cardiac disease and mild anemia (baseline hct ap-quent. In group A, one new antihypertensive medication
proximately 30%) does not appear to be associated withwas added over the course of the study in one patient,
increased BP as measured by either ABP monitoring orand in two patients, a single antihypertensive medication
routine BP measurements by the dialysis unit staff. Awas discontinued. In group B, four patients had single
hypertensive effect of normalization of hematocrit wasnew antihypertensives added, whereas in two patients,
also not apparent in the larger multicenter trial [10] insingle antihypertensives were discontinued.
which our patients were enrolled. Few studies using ABPThere was little diurnal variation in mean ambulatory
monitoring to study the effects of partially correctingSBP and DBP in either group at baseline or after correc-
anemia with epoetin in hemodialysis patients have beention of anemia to normal hct levels in group A (Fig. 1).
published. A trend toward increased 24-hour postdialysisAt two months, one patient in group A had a nocturnal
ABP, mainly due to an increase in nighttime SBP andfall in DBP of more than 10% compared with daytime,
DBP, followed partial correction of anemia over approx-whereas such a change was not seen in any of the group
imately 18 weeks in one small study [3]. In a study ofB patients at two months. There were no patients in
either group with a nocturnal fall of SBP of more than 13 hemodialysis patients before and after three to four
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Fig. 1. Daytime (j) and nighttime (h) mean
ambulatory systolic (SBP) and diastolic
(DBP) blood pressures in group A patients
at each study period (mean 6 SEM). P , 0.05
for daytime vs. nighttime DBP at month 12
only.
months of epoetin, in which hct increased from 24.5 6 In this study, although mean 24-hour SBP, daytime
SBP, and nighttime SBP tended to be higher at 2, 4, 8,1.0% to 32.0 6 1.1%, daytime and nighttime SBP and
nighttime DBP were higher at the end of epoetin therapy and 12 months in group A compared with group B, this
did not reach statistical significance and appeared to bethan prior to the treatment of anemia [4].
In a short-term study of 32 hemodialysis patients, ABP due to an unexplained trend toward slightly lower mean
systolic ABP parameters in group B at months 2 and 4was assessed with a device that measured finger BP be-
fore and then after seven to eight weeks of epoetin in compared with baseline. In group A, ABP values by
paired analysis were unchanged at 2, 4, 8, and 12 monthswhich hct was increased from 20.9 6 2.1% to 26.2 6
2.1%. In 20 of the patients, mean ABP rose by 5 mm Hg compared with baseline. Importantly, BPs in group A
were stable over the first four months, as a normal hctor more. In the remaining 12 patients, the mean ambula-
tory SBP and DBP were lower at the end of follow-up was being achieved, and at subsequent observations, as
a normal hct was maintained, despite little change in[7]. Epoetin-induced hypertension (a mean daytime SBP
increase of more than 20 mm Hg or a DBP increase antihypertensive therapy or postdialysis “dry weight.”
There are several factors that might explain the ab-of more than 10 mm Hg or requirement for additional
antihypertensive therapy) was reported in 5 of 12 hemo- sence of an effect in ABP parameters in our study,
whereas prior studies with ABP monitoring found andialysis patients as hct increased from 25 to 34% in an-
other short-term study [5]. effect on BP of partial correction of anemia with epoetin
in hemodialysis patients. In the earlier studies, baselineLebel et al studied 13 hemodialysis patients before
[mean hemoglobin (hgb) 8.2 6 0.3 g/dl] and after three ABP monitoring was performed prior to the initiation
of epoetin therapy while patients were more severelyto four months of epoetin (mean hgb 11.4 6 0.3 g/dl)
[6]. With higher hcts, the mean 24-hour SBP and DBP, anemic than at the start of this trial. In our study, all
patients had been receiving epoetin for at least threedaytime SBP and DBP, and nighttime DBP were higher
than prior to epoetin therapy. months and were less anemic at baseline, with mean
hct values of approximately 30%. Thus, there may be aThese same authors more recently performed ABP
monitoring before epoetin therapy (mean hgb 8.3 6 0.15 hypertensive effect of raising the hct from the low-mid
20s to higher (albeit still anemic) levels, but perhapsg/dl) and 10 to 23 weeks later after a target hgb of 11
to 12 g/dl had been reached [8]. All ABP (24 hr, daytime, because of differences in cardiovascular hemodynamic
responses, raising the hct from about 30% to normalnighttime) parameters were significantly higher after
epoetin therapy. The authors concluded that sodium- levels was not associated with a significant hypertensive
response.and volume-dependent mechanisms were likely respon-
sible for most of the observed hypertensive response, In early clinical trials with epoetin, the mean hct values
typically increased by approximately 1.0 to 1.5 hct vol-which was most prominent in patients with hypertension
or who were receiving antihypertensive therapy at base- ume percent per week [1, 2]. The mean rate of rise of
hct in group A patients in our study was 0.6 hct vol %line.
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per week over 8 weeks and 0.5 hct vol % per week over [6, 8] and Imai et al [7], partial treatment of anemia with
epoetin did not appear to significantly affect diurnal BP16 weeks. This is about the same rate as in the studies
of Imai et al [7] and van de Borne et al [4], but somewhat patterns in hemodialysis patients with either normal or
blunted baseline circadian rhythms. In contrast, van delower than that in the studies of Lebel et al [6, 8] and
Abraham et al [3]. Additionally, in this study, all partici- Borne et al found that although a nocturnal decline in
SBP in anemic hemodialysis patients persisted after par-pants had documented cardiac disease, whereas in earlier
studies the presence or absence of cardiac disease was tial correction of anemia, a nocturnal decline in DBP
that was present prior to treatment with epoetin was nonot a specific criterion for study enrollment. The slow
erythropoietic response and the presence of cardiac dis- longer evident after partial correction of anemia [4].
Amar et al reported that a greater proportion of “non-ease in our patients may account for the absence of a
hypertensive effect with increased hct in this study. It is dippers” (no nocturnal BP decline) than “dippers” (noc-
turnal BP decline present) were receiving epoetin,highly unlikely that further follow-up beyond 12 months
would have affected our results or conclusions. Eighty- although hgb levels were not different, raising the possi-
bility that epoetin itself may affect nocturnal BP patternsnine percent of group A patients were at the target hct
of 42 6 3% during month 8 and 86% were during month [16]. Throughout our study, there was little difference
between daytime and nighttime SBPs or DBPs, and most12. Analysis of only those group A patients with hct in
the 42 6 3% range at months 4, 8, and 12 did not detect patients did not have a significant decline in nighttime
SBP or DBP at baseline or after correction of anemiastatistically significant increases in any BP parameter
compared with baseline. Furthermore, all mean BP pa- to normal in group A patients. Although the mean night-
time DBP was lower than the mean daytime DBP at 12rameters in group A patients were quite stable between
months 8 and 12 (Table 2). months in group A, the difference was small. Further
long-term studies would be necessary to determineWeekly epoetin doses were as much as 7.5 times higher
in group A than group B, yet we did not detect a signifi- whether sustained maintenance of normal hct levels be-
yond the 12 months of this study is associated with thecant increase in ABP or routine dialysis unit BP parame-
ters. A direct pressor effect of epoetin has been suggested appearance of normal diurnal BP patterns in hemodialy-
sis patients.[25]. Others have reported that epoetin is not directly
vasoconstrictive, but enhances vascular responsiveness Our study is limited by the small number of patients,
especially after 8 and 12 months of follow-up. We cannotin vitro by increasing the release of endothelin-1 and
vasoconstrictor prostanoids and decreasing the release completely exclude the possibility that small differences
or changes in BP could have been missed. However, aof prostacyclin [26–28]. Studies in hemodialysis patients
have been conflicting. For instance, epoetin was reported post hoc power analysis indicates that even with the
reduced number of patients still enrolled at months 8to increase BP and endothelin levels, particularly when
the drug is given intravenously [29, 30], to leave endo- and 12, there was an 80% probability of detecting at least
a 20% difference in SBP. The absence of a hypertensivethelin levels unchanged [8, 31], and to even reduce vascu-
lar responsiveness to endothelin-1 [31]. response to higher hct levels cannot be attributed to
reduced dry weights or increased antihypertensive thera-Many authors have suggested an absence or blunting
of normal circadian BP variation in patients with chronic pies in group A patients. Because there were no consis-
tent or persistent trends in BP patterns with either ABPrenal failure [11–16, 18, 19, 32], although this has not
been a consistent finding [17, 20–22, 33]. Factors such or dialysis unit BP measurements and we found no differ-
ences of statistical significance within or between groups,as changing volume status over the interdialytic period,
effects of the dialysis treatment itself (including volume it seems unlikely that clinically important BP effects of
normal hct went undetected.removal or interruption of diurnal patterns by sleep dur-
ing dialysis), presence or absence of baseline hyperten- A few comments regarding the day/night time periods
used in our study are in order. In normal subjects (thatsion, and concomitant antihypertensive medication use
may affect diurnal BP patterns in hemodialysis patients is, patients without renal failure and who are not on
dialysis), various definitions of waking and sleeping peri-and may explain some of the differences seen between
studies. Elisaf et al, for example, found that normoten- ods have been applied to ABP monitoring [reviewed in
34], with no consensus as to the optimal time periods.sive hemodialysis patients had normal diurnal BP pat-
terns during the first posthemodialysis day, which were Sleep disturbances are common in dialysis patients [35,
36], so defining appropriate waking-sleeping intervals inthen abnormal on the subsequent day. Hypertensive pa-
tients did not have normal circadian BP patterns on hemodialysis patients is problematic. Patients sleep while
on dialysis and fall asleep and wake at widely varyingeither day [18].
The effect of epoetin treatment and partial correction times from patient-to-patient (for example, early morn-
ing dialysis shift vs. evening dialysis shift) and probablyof anemia on the diurnal BP pattern in hemodialysis
patients is also not clear. In the studies of Lebel et al day-to-day (for example, dialysis day vs. nondialysis day)
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normotensive and in untreated borderline hypertensive hemodialy-for individual patients. Thus, we have chosen for our
sis patients. Am J Hypertens 8:545–551, 1995
study not to define waking and sleeping intervals, but 7. Imai Y, Sekino H, Fujikura Y, Munakata M, Minami N, Hashi-
moto J, Sakuma H, Watanabe N, Misawa S, Nishiyama A, Aberather daytime and nighttime intervals, acknowledging
K: Pressor effect of recombinant human erythropoietin: Resultsthat the intervals chosen do not reflect sleep-awake pat-
of ambulatory blood pressure monitoring and home blood pressure
terns in our patients. Because of the small number of measurements. Clin Exp Hypertens 17:485–506, 1995
8. Lebel M, Kingma I, Grose JH, Langlois S: Hemodynamic andpatients involved, we do not believe that analysis of
hormonal changes during erythropoietin therapy in hemodialysisour data with respect to actual sleep patterns would
patients. J Am Soc Nephrol 9:97–104, 1998
be meaningful and would be impossible retrospectively 9. NKF-DOQI clinical practice guidelines for the treatment of anemia
of chronic renal failure. Am J Kidney Dis 30(Suppl 3):S192–S240,because diaries were not recorded by patients.
1997A final point worth noting is that repeated interdialytic
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